Therapeutic programs / licensing

Our own programs,
built on the fabric.

We don’t only sell the fabric. Each program below started as a question in Omic, and each is available for licensing.

MYR-001Fully Owned
Cancer & infectious disease
Oncology & Infectious Disease
A small-molecule program targeting protein N-myristoylation, a dependency shared across certain cancers and infectious agents.
Target
Undisclosed (myristoylation pathway)
Modality
Small Molecule
Lead Optimization2 of 7 to approval
GLC-001Fully Owned
Glaucoma
Ophthalmology
A small-molecule program aimed at restoring aqueous outflow through the trabecular meshwork to lower intraocular pressure in glaucoma.
Target
Undisclosed (trabecular meshwork outflow)
Modality
Small Molecule
Lead Optimization2 of 7 to approval
IMO-001Fully Owned
Solid tumors
Oncology (Immuno-oncology)
A small-molecule trispecific program designed to engage multiple targets at once in solid tumors.
Target
Undisclosed (trispecific)
Modality
Small Molecule
Lead Optimization2 of 7 to approval
GPR-001Fully Owned
Inflammatory pain & sickle-cell vaso-occlusive crisis
Inflammation & Hematology
A small-molecule program targeting GPR55 to address inflammatory pain and sickle-cell vaso-occlusive crises.
Target
GPR55
Modality
Small Molecule
Lead Optimization2 of 7 to approval

Computational programs. Experimental and clinical validation are separate steps, and each program page says which it has reached.